Michalska-Falkowska Anna, Niklinski Jacek, Juhl Hartmut, Sulewska Anetta, Kisluk Joanna, Charkiewicz Radoslaw, Ciborowski Michal, Ramlau Rodryg, Gryczka Robert, Piwkowski Cezary, Kozlowski Miroslaw, Miskiewicz Borys, Biecek Przemyslaw, Wnorowska Karolina, Dzieciol-Anikiej Zofia, Sargsyan Karine, Naumnik Wojciech, Mroz Robert, Reszec-Gielazyn Joanna
Biobank, Medical University of Bialystok, 15-269 Bialystok, Poland.
Indivumed Services, 20251 Hamburg, Germany.
Cancers (Basel). 2023 Jul 24;15(14):3742. doi: 10.3390/cancers15143742.
Biobanks are vital for high-throughput translational research, but the rapid development of novel molecular techniques, especially in omics assays, poses challenges to traditional practices and recommendations. In our study, we used biospecimens from oncological patients in Polish clinics and collaborated with the Indivumed Group. For serum/plasma samples, we monitored hemolysis, controlled RNA extraction, assessed cDNA library quality and quantity, and verified NGS raw data. Tissue samples underwent pathologic evaluation to confirm histology and determine tumor content. Molecular quality control measures included evaluating the RNA integrity number, assessing cDNA library quality and quantity, and analyzing NGS raw data. Our study yielded the creation of distinct workflows for conducting preanalytical quality control of serum/plasma and fresh-frozen tissue samples. These workflows offer customization options to suit the capabilities of different biobanking entities. In order to ensure the appropriateness of biospecimens for advanced research applications, we introduced molecular-based quality control methods that align with the demands of high-throughput assays. The novelty of proposed workflows, rooted in innovative molecular techniques, lies in the integration of these QC methods into a comprehensive schema specifically designed for high-throughput research applications.
生物样本库对于高通量转化研究至关重要，但新型分子技术的快速发展，尤其是在组学分析方面，给传统做法和建议带来了挑战。在我们的研究中，我们使用了波兰诊所肿瘤患者的生物样本，并与Indivumed集团合作。对于血清/血浆样本，我们监测溶血情况、控制RNA提取、评估cDNA文库的质量和数量，并验证NGS原始数据。组织样本进行了病理评估，以确认组织学并确定肿瘤含量。分子质量控制措施包括评估RNA完整性数值、评估cDNA文库的质量和数量以及分析NGS原始数据。我们的研究产生了用于对血清/血浆和新鲜冷冻组织样本进行分析前质量控制的不同工作流程。这些工作流程提供了定制选项，以适应不同生物样本库实体的能力。为了确保生物样本适用于高级研究应用，我们引入了符合高通量分析要求的基于分子的质量控制方法。所提出的工作流程的新颖之处在于，其基于创新的分子技术，将这些质量控制方法整合到一个专门为高通量研究应用设计的综合方案中。
